A novel coronavirus (CoV) known as severe acute respiratory syndrome CoV type 2 is the causative agent for the development of CoV disease 2019 (Covid‐19). Covid‐19 may increase the risk of developing pulmonary histoplasmosis due to immune dysregulation. In addition, Covid‐19 may enhance the propagation of acute pulmonary histoplasmosis due to lung injury and inflammation, and using corticosteroids in severely affected Covid‐19 patients may reactivate latent pulmonary histoplasmosis. Likewise, activation of inflammatory signaling pathways during H. capsulatum infection may increase the severity of Covid‐19 and vice versa. Furthermore, lymphopenia in Covid‐19 may increase the risk for the progress of pulmonary histoplasmosis besides activation of inflammatory signaling pathways during H. capsulatum infection may increase the severity of Covid‐19 and vice versa. Therefore, this critical review aimed to find the potential link between Covid‐19 pneumonia and pulmonary histoplasmosis concerning the immunological response.
Insights on Covid‐19 with superimposed pulmonary histoplasmosis: The possible nexus
Y. A. Almutawif,H. Al-kuraishy,A. Al-Gareeb,Athanasios Alexiou,M. Papadakis,Hamza M. A. Eid,H. Saad,G. Batiha
Published 2023 in Immunity, Inflammation and Disease
ABSTRACT
PUBLICATION RECORD
- Publication year
2023
- Venue
Immunity, Inflammation and Disease
- Publication date
2023-09-01
- Fields of study
Medicine, Environmental Science
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
CITED BY
Showing 1-2 of 2 citing papers · Page 1 of 1